- Zacks Small Cap Research•4 months ago
For the year ended December 31, 2015, substantially all of the revenue we recognized consisted of pharmacogenomics testing by the NRLBH. As a result of the sale of the NRLBH, the revenue and cost of revenue is presented as discontinued operations for both years ended 2015 and 2014. The NLRBH had a total net revenue of $5.5 million for the year ended December 31, 2015 consisting of mainly pharmacogenomics testing.
|Bid||0.15 x 1000|
|Ask||0.43 x 600|
|52wk Range||0.14 - 1.23|
|Day's Range||0.28 - 0.29|
|Avg Vol (3m)||325,944|
As of 4:00 PM EDT. Market closed.